Bio Diagnostics Company Investment Opportunity in Phoenix, United States

- Business primarily focused on gene therapy and biomarker/diagnostic services, with a specific emphasis on neurological conditions such as ALS, Parkinson's, Alzheimer's, and TBI.

- Offers biomarker testing as a CRO for pharma and researchers. Additionally, it is involved in the development of Adeno-Associated Viruses (AAVs) for neurodegenerative disorders, with a particular focus on inflammation and targeting neurons and glial cells.

- Has patented and licensed technologies from premier research institutions.

- The company generates revenue on a per research project basis, with an average project duration of 3 months and an average value ranging from $8,000 to $25,000. It has successfully completed projects for 10 different research companies since its inception.

- The company is currently engaged in a gene therapy research project involving 2,600 samples.

- There are 2 permanent employees, additionally, we have a few temporary employees/interns as well.

Biomarker testing as a CRO for pharma and researchers and developing AAVs for neurodegenerative disorders with a focus on inflammation including targeting neurons and glial cells.

Physical assets include lab equipment and furniture.

Currently operate out of a rented facility in a small hospital-owned CLIA lab in Thomas Road,

Phoenix.

Funded through CRO biomarker revenues and non-dilutive capital.

Clean cap table with 7 individual shareholders with no shareholder owning more than 30%.